CD4
+ regulatory T (Treg) cells expressing CD25 and the transcription factor forkhead box P3 (FOXP3) are indispensable for immunological self-tolerance and homeostasis. FOXP3
+ T cells in humans, however, are heterogeneous in function and differentiation status, including suppressive or nonsuppressive cells as well as resting or activated Treg cells. We have searched for cell surface markers specific for suppression-competent Treg cells by using a panel of currently available monoclonal antibodies reactive with human T cells. We found that CD15s (sialyl Lewis x) was highly specific for activated, terminally differentiated, and most suppressive FOXP3 high effector Treg (eTreg) cells and able to differentiate them in various clinical settings from nonsuppressive FOXP3 + T cells secreting inflammatory cytokines. For example, CD15s
+ eTreg cells were increased in sarcoidosis, whereas it was nonsuppressive CD15s 
+ T cells in humans are heterogeneous in phenotype and function (2) . For example, any human conventional CD4
+ T cell can transiently up-regulate FOXP3 upon activation; such FOXP3 + T cells are hardly suppressive (3) . In addition, not all FOXP3-expressing CD4 + T cells in peripheral blood mononuclear cells (PBMCs) possess suppressive function (4) . It is therefore imperative to determine how functionally and developmentally distinct human FOXP3 + subpopulations can be reliably delineated to better understand the roles of Treg cells in immunological diseases and to specifically target them for the control of pathological and physiological immune responses.
Efforts secreting FOXP3 low non-Treg population, can be more discretely and reliably differentiated by specific molecular markers, especially, those expressed on the cell surface. This is critically important in analyzing the possible contribution of Treg cells to the dynamics of immune responses and preparing a pure suppression-competent Treg cell preparation for cell therapy of immunological diseases.
In 
+ T cells (Fig. 1C) . These analyses revealed that CD15s was the marker most specifically expressed by FOXP3 + cells, in particular by CD45RA − cells with the highest FOXP3 MFI. In addition, in contrast with CD15s, FOXP3 + T cells scarcely expressed nonsialylated CD15 (Fig. 1D) . Our search for markers that were preferentially down-regulated by eTreg cells, compared with conventional CD4 + T cells, identified seven markers, i.e., CD26, CD55, CD100, CD130, CD221, CD305, and CD321; none of them was, however, as discriminative as CD127 (12, 13) (Figs. S1 and S4) .
Comparison of surface markers with intracellular expression of the proliferation marker Ki-67 or the transcription factor Helios revealed a correlation between Ki-67 and CD71, ICOS, or ICOS-L, and between Helios and CD39 in some, but not all, healthy donors (Figs. S2, S3, and S5).
Use of CD15s and CD45RA indeed enabled us to dissect FOXP3 +
+ T cells into three discrete fractions; that is, CD15s (Fig. 1G) .
Taken together, within the FOXP3 + population, CD15s represents a specific cell surface marker for eTreg cells, which are CD15s 
+ T cells and CD15s Fig. 2A) . The CD15s + population expressed the highest level of FOXP3 ( Fig. 2A) and was highly suppressive, whereas the CD15s − population exhibited the lowest level of FOXP3 expression and lacked significant suppressive function ( Fig. 2B and Fig. S6 ). We also examined in vitro whether CD15s expression could be induced in naïve Treg cells and/or FOXP3 + T cells derived from conventional T cells, by T-cell receptor (TCR) stimulation in the presence of high dose IL-2 and rapamycin (14, 15 
CD15s
+ T-Cell Depletion Induces Tumor Antigen-Specific CD4 + T-Cell
Responses and Enhances Antiviral CD8
+ T-Cell Responses in Vitro. We next attempted to determine whether CD15s was able to define Treg cells suppressing antitumor or antiviral responses. We depleted CD15s
+ cells from healthy donor CD4 + T cells and stimulated the remaining cells for 20 d with autologous X-irradiated T-cell depleted PBMCs pulsed with peptides from the NY-ESO-1 protein, an antigen commonly expressed by human germ-line cells and cancer cells (17) . CD15s-expressing cell depletion markedly enhanced the induction of IFNγ-producing CD4 + T cells measured by ELISPOT assay (Fig. 4 A and B) . In addition, similar CD15s
+ cell depletion and subsequent antigen stimulation enhanced in vitro immune responses of an HLA-A2 + individual against an HLA-A2-restricted cytomegalovirus (CMV) antigen as illustrated by a marked increase in the proportion of CMV-HLA-A2 tetramer positive cells among CD8 + T cells (Fig. 4C) . These results collectively indicate that CD15s is a specific marker for suppression-competent eTreg cells and can be useful for boosting antitumor or antiviral T-cell responses. Sjögren syndrome, systemic sclerosis, myasthenia, and mycosis fungoides (MF) (Fig. 5A) 
FOXP3
+ non-Treg cells in active SLE, were confirmed with individual samples obtained from healthy donors (n = 8) and patients with sarcoidosis (n = 8) or SLE (n = 8) (Fig. 5B) . Notably, although the ratio of CD15s + eTreg cells significantly increased, their absolute numbers were significantly lower in SLE patients compared with healthy donors, a result consistent with previous observations (4, 19, 20) (Fig. 5C) . Functionally, FOXP3 low cells, in particular CD15s
+ T cells from individuals with SLE flares actively produced IL-2 and IFN-γ as observed in healthy donors (Fig. 1F) , whereas CD15s
+ cells did not (Fig. 5D ). Altogether, these data demonstrate that CD15s expression allows a clear segregation between eTreg and non-Treg cells, even in conditions associated with FOXP3 +
CD4
+ T-cell expansions.
Discussion
We have shown in this report that CD15s is highly specifically expressed by suppression-competent FOXP3 + eTreg cells but not by nonsuppressive FOXP3 + non-Treg T cells. CD15s is therefore useful for assessing dynamic changes in the FOXP3 + regulatory/nonregulatory T-cell balance in physiological and disease states. In addition, finer tuning of immune responses can be achieved by targeting CD15s-expressing FOXP3 + eTreg cells, rather than whole FOXP3 + cells. CD15s (sialyl Lewis x), a tetrasaccharide carbohydrate, is the α2-3 sialylated form of lacto-N-fucopentaose III (CD15) (21) . In addition to eTreg cells and some memory and/or activated T cells, CD15s is highly expressed on monocytes, neutrophils, and some myeloid precursors (22) . The carbohydrate nature of this antigen explains why previous transcriptome analyses of Tregspecific markers failed to identify the CD15s molecule (4, 23) . In addition, eTreg cells do not express CD15, which is nonsialylated. CD15s and CD15 synthesis is mediated by fucosyltransferase 7 (FUT7) and fucosyltransferase 9 (FUT9), respectively (24) (25) (26) . Our previous transcriptome analysis of FOXP3-expressing CD4 T cells indeed showed that FUT7 was highly expressed by eTreg cells, compared with other FOXP3 + or FOXP3 − subsets, whereas FUT9 was not expressed by CD4 + T cells (4) . This indicates that CD15 sialylation is highly specific for eTreg cells. Functionally, CD15s is a ligand for selectins and is involved in the cellular interaction with endothelial cells, promoting the migration of CD15s + lymphocytes from the peripheral blood into the tissues (27) . Murine CD4 +
CD25
+ Treg cells isolated from FUT7 −/− mice were unable to prevent a delayed type hypersensitivity reaction (28) . CD15s does not appear to play a significant role in Treg-mediated suppression because eTreg cells coated with anti-CD15s mAb for their isolation, hence blocked in their interaction with selectin, exhibited an equivalent in vitro suppressive activity as eTreg cells isolated by CD45RA and CD25 expression. Taken together, CD15s is likely involved in the transmigration of eTreg cells toward target tissues to suppress tissue-localized inflammation.
We have previously shown that FOXP3-expressing CD4 + T cells, which are completely demethylated at the Treg-specific demethylated region of the FOXP3 gene, are highly suppressive, whereas FOXP3 low CD4 + T cells, which were hardly demethylated at the region, failed to show suppressive activity. The latter appear to correspond to, or at least include, those conventional T cells with an activation-induced FOXP3 expression, which is not high enough to induce a suppressive function (2) . FOXP3 high CD4
+ T cells include Treg cells expressing HLA-DR and/or ICOS. HLA-DR expression reportedly characterizes highly and rapidly suppressive Treg cells (6) , whereas ICOS + cells appear to be more prone to produce IL-10 (5). ICOS expression was found to be highly correlated with Ki-67 expression in the present study, indicating that ICOS expression may primarily be a proliferation marker rather than a marker defining a specific eTreg population. In addition, it was proposed that the transcription factor Helios could represent a marker for thymus-derived Treg cells (8) , although conventional CD4 + T cells with induced expression of FOXP3 and other activated CD4 + T cells can also express Helios (29) (30) (31) . We have failed to find a specific surface marker associated with Helios expression, although CD39 showed a correlation in some healthy donors but not in others. A recent study reported TIGIT as a specific marker for highly suppressive Treg cells in both mice and humans (32 + eTreg cells appear to be derived in vivo from CD15s − CD45RA + nTreg cells (4), our finding that in vitro TCR stimulation in the presence of IL-2 and rapamycin enhanced FOXP3 expression but failed to efficiently up-regulate CD15s in nTreg cells suggests that longer or additional stimulations might be required for CD15s up-regulation and possibly for final eTreg maturation. It is therefore required, especially in vitro, to use CD15s in combination with other markers such as CD25, CD127, and CD45RA for the analysis and purification of FOXP3 + subpopulations. CD15s also enables the analysis of the behavior and dynamics of Treg subsets in disease states more accurately and clearly than before. For example, using CD15s as a specific marker for eTreg cells, our analysis has shown that previous estimates of eTreg cell numbers (based on the expression of FOXP3, CD45RA, and Ki-67) are largely similar in healthy donors to the current estimates, but slightly overestimated in sarcoidosis (33) and slightly underestimated in SLE (20) 
Methods
Flow Cytometry Analysis of FOXP3-, Ki-67-, and Helios-Expressing CD4 + T Cells.
Blood samples were obtained from young healthy adult volunteers and patients with active sarcoidosis, active SLE, Sjögren syndrome, systemic sclerosis, mycosis fungoides, or myasthenia gravis. The study was done according to the Helsinki declaration with the approval from the local human ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale of Pitié-Salpétrière Hospital, Paris). For the analysis of thymocytes, the approval by the Biomedecine Agency (PFS13-007) was obtained. Cytometry methods and mAbs are detailed in Dataset S1 and SI Methods.
Suppression Assay. PBMCs were isolated through Ficoll gradient separation from freshly drawn blood. CD4 + T cells were first magnetically isolated using a CD4 + T-cell separation kit (Miltenyi Biotec) and subsequently surface stained using a combination of flurochrome-conjugated mAbs: anti-CD4-PErCP 5.5, -CD25-PE, -CD127-Pacific blue (Human Regulatory T-Cell Mixture, BD Biosciences), -CD45RA-PECy7, and -CD15s-AF647 obtained from BD Biosciences. CD127 T cells according to the gating strategy depicted in Fig. 2A . CFSE labeling and suppression assays were performed as described in SI Methods. Complete suppression is characterized by fewer proliferation cycles and decreasing amplitudes in consecutive cycle peaks, whereas ongoing proliferation or absence of suppression is characterized by increasing amplitudes in consecutive cycle peaks. + nTregs were immediately distributed into a U-bottom well for culture. Cells were cultured in X-Vivo 15 media (Lonza) with 50 g/L AB serum (Invitrogen Lifetech), and supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acid MEM, 100 units/mL penicillin, 100 μg/mL streptomycin and amphotericin B (all from Gibco), and anti-CD3/anti-CD28-coated Treg expander beads (Invitrogen Lifetech), in the presence of 300 IU/mL IL-2 (Miltenyi Biotec) in culture media alone or in the presence of rapamycin (Sigma-Aldrich) diluted in culture medium (1 μg/mL).
Cultures were replenished with 300-1,000 IU/mL IL-2 every 3-4 d.
In Vitro Sensitization of NY-ESO-1-Specific CD4 + T Cells and in Vitro Sensitization of CMV-Specific CD8 + T Cells. Methods are detailed in SI Methods.
Statistical Analysis. To compare the percentage of cell subsets in healthy donors versus patients, a nonparametric Mann-Whitney u test was used. P < 0.05 was considered significant.
